Literature DB >> 27239027

Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model.

In Young Choi1, HoTae Lim1, Kenneth Estrellas2, Jyothi Mula3, Tatiana V Cohen3, Yuanfan Zhang2, Christopher J Donnelly4, Jean-Philippe Richard5, Yong Jun Kim6, Hyesoo Kim7, Yasuhiro Kazuki8, Mitsuo Oshimura9, Hongmei Lisa Li10, Akitsu Hotta11, Jeffrey Rothstein12, Nicholas Maragakis5, Kathryn R Wagner13, Gabsang Lee14.   

Abstract

Duchenne muscular dystrophy (DMD) remains an intractable genetic disease. Althogh there are several animal models of DMD, there is no human cell model that carries patient-specific DYSTROPHIN mutations. Here, we present a human DMD model using human induced pluripotent stem cells (hiPSCs). Our model reveals concordant disease-related phenotypes with patient-dependent variation, which are partially reversed by genetic and pharmacological approaches. Our "chemical-compound-based" strategy successfully directs hiPSCs into expandable myoblasts, which exhibit a myogenic transcriptional program, forming striated contractile myofibers and participating in muscle regeneration in vivo. DMD-hiPSC-derived myoblasts show disease-related phenotypes with patient-to-patient variability, including aberrant expression of inflammation or immune-response genes and collagens, increased BMP/TGFβ signaling, and reduced fusion competence. Furthermore, by genetic correction and pharmacological "dual-SMAD" inhibition, the DMD-hiPSC-derived myoblasts and genetically corrected isogenic myoblasts form "rescued" multi-nucleated myotubes. In conclusion, our findings demonstrate the feasibility of establishing a human "DMD-in-a-dish" model using hiPSC-based disease modeling.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27239027     DOI: 10.1016/j.celrep.2016.05.016

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  77 in total

1.  Micropatterned substrates with physiological stiffness promote cell maturation and Pompe disease phenotype in human induced pluripotent stem cell-derived skeletal myocytes.

Authors:  Nunnapas Jiwlawat; Eileen M Lynch; Brett N Napiwocki; Alana Stempien; Randolph S Ashton; Timothy J Kamp; Wendy C Crone; Masatoshi Suzuki
Journal:  Biotechnol Bioeng       Date:  2019-06-20       Impact factor: 4.530

2.  Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy.

Authors:  Madhurima Saha; Skylar A Rizzo; Manashwi Ramanathan; Rylie M Hightower; Katherine E Santostefano; Naohiro Terada; Richard S Finkel; Jonathan S Berg; Nizar Chahin; Christina A Pacak; Richard E Wagner; Matthew S Alexander; Isabelle Draper; Peter B Kang
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

3.  Differentiation and sarcomere formation in skeletal myocytes directly prepared from human induced pluripotent stem cells using a sphere-based culture.

Authors:  Saowanee Jiwlawat; Eileen Lynch; Jennifer Glaser; Ivy Smit-Oistad; Jeremy Jeffrey; Jonathan M Van Dyke; Masatoshi Suzuki
Journal:  Differentiation       Date:  2017-08-01       Impact factor: 3.880

Review 4.  Pluripotent stem cell-based gene therapy approach: human de novo synthesized chromosomes.

Authors:  Sergey A Sinenko; Sergey V Ponomartsev; Alexey N Tomilin
Journal:  Cell Mol Life Sci       Date:  2020-10-03       Impact factor: 9.261

Review 5.  Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies.

Authors:  Sridhar Selvaraj; Michael Kyba; Rita C R Perlingeiro
Journal:  Trends Mol Med       Date:  2019-09       Impact factor: 11.951

6.  ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs.

Authors:  Michael R Hicks; Julia Hiserodt; Katrina Paras; Wakana Fujiwara; Ascia Eskin; Majib Jan; Haibin Xi; Courtney S Young; Denis Evseenko; Stanley F Nelson; Melissa J Spencer; Ben Van Handel; April D Pyle
Journal:  Nat Cell Biol       Date:  2017-12-18       Impact factor: 28.824

7.  A Myogenic Double-Reporter Human Pluripotent Stem Cell Line Allows Prospective Isolation of Skeletal Muscle Progenitors.

Authors:  Jianbo Wu; Nadine Matthias; Jonathan Lo; Jose L Ortiz-Vitali; Annie W Shieh; Sidney H Wang; Radbod Darabi
Journal:  Cell Rep       Date:  2018-11-13       Impact factor: 9.423

8.  Duchenne muscular dystrophy hiPSC-derived myoblast drug screen identifies compounds that ameliorate disease in mdx mice.

Authors:  Congshan Sun; In Young Choi; Yazmin I Rovira Gonzalez; Peter Andersen; C Conover Talbot; Shama R Iyer; Richard M Lovering; Kathryn R Wagner; Gabsang Lee
Journal:  JCI Insight       Date:  2020-06-04

Review 9.  Correction of muscular dystrophies by CRISPR gene editing.

Authors:  Francesco Chemello; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

10.  Tempol improves redox status in mdx dystrophic diaphragm muscle.

Authors:  Túlio de Almeida Hermes; Daniela Sayuri Mizobuti; Guilherme Luiz da Rocha; Heloina Nathalliê Mariano da Silva; Caroline Covatti; Elaine Cristina Leite Pereira; Renato Ferretti; Elaine Minatel
Journal:  Int J Exp Pathol       Date:  2020-10-24       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.